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The role of consolidation chemotherapy after concurrent chemo-radiation (chemo-RT) for patients with unresected stage III non–small-cell lung cancer (NSCLC) remains 
only partially defined. Issues exist with respect to the heterogeneity of this patient popula-
tion as well as of the nature of the therapies received, thus making global policies difficult 
to formulate and even more difficult to execute. Dr. Tsujino and colleagues1 have tried to 
address this by ambitiously gathering over 3400 patients from 41 studies and segregating 
their survival outcome by whether or not they were assigned to receive consolidation che-
motherapy. The trials analyzed included mainly single-arm phase II trials, with only seven 
phase III studies in this data set. The authors conclude from their analysis that the intent to 
give consolidation chemotherapy was not associated with better survival outcome.
The authors acknowledge a number of limitations of this report. These obviously 
include patient and treatment regimen variability across a very diverse set of trials. I believe 
there are more important issues to consider. This analysis includes concurrent chemo-RT 
regimens with the so-called radiosensitizing regimens of low-dose weekly carboplatin-
based chemotherapy as well as the full-dose every-3-week cisplatin-based chemotherapy 
regimens. It is a widely held belief that the benefit as well as the tolerance of consolidation 
chemotherapy may be different after such different chemo-RT regimens. Because patients 
receiving low-dose weekly chemotherapy during RT therapy have yet to receive systemic 
levels of chemotherapy, most current clinical trials using these regimens do include consol-
idation chemotherapy. The fuller-dose cisplatin-based chemotherapy chemo-RT regimens 
form the basis for the benefit of concurrent over sequential chemo-RT and did not include 
consolidation chemotherapy.2,3 The three trials that prospectively isolated the consolida-
tion chemotherapy question in a randomized question have not provided support for this 
approach after full-dose chemotherapy during chemo-RT.4–6
Many of the interesting observations in this report highlight the challenges of such a 
retrospective analysis. There was a difference in survival outcome among the time periods 
of study conduct, perhaps as a reflection of improvements in staging and supportive care, 
and there were differences by regions of the world, with patients in East Asian trials hav-
ing the longest survival. Both of these observations emphasize the value of using individ-
ual patient data when possible in conducting a meta-analysis. Also realize the two patient 
cohorts in this analysis were segregated by intent to deliver consolidation chemotherapy 
rather than the actual delivery. Most reports demonstrate that half or less of any planned 
consolidation chemotherapy is delivered after chemo-RT as planned.
Will this report influence decision making regarding consolidation chemotherapy for 
stage III NSCLC patients? Probably not. Physicians delivering low-dose weekly chemother-
apy during RT to good performance status patients will still attempt to deliver consolidation 
chemotherapy, and those delivering full-dose chemotherapy during RT probably will not. 
As the authors accurately state, there have been no new observations that have changed the 
standard care of concurrent chemo-RT for this large cohort of lung cancer patients. Several 
new trials for stage III NSCLC patients are underway or in development, which account 
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for the presence or absence of certain tumor mutations in trial 
design and execution. Hopefully, such approaches will favor-
ably influence the current survival plateau in this disease.
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